Noticias de EXEL_US

Noticias del mercado

Últimas noticias sobre EXEL_US — 77 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: EXEL_US ✕ 77 resultados
10/02/2026 EXEL_US — ChartMill
Exelixis Inc (NASDAQ:EXEL) Reports Mixed Q4 2025 Results, Beats on EPS but Misses on Revenue
10/02/2026 EXEL_US — Investing.com
Earnings call transcript: Exelixis Q4 2025 reports EPS beat, stock dips
10/02/2026 EXEL_US — Yahoo Finance ES ← EN
Aspectos destacados de la convocatoria de resultados del cuarto trimestre de 2025 de Exelixis Inc (EXEL): fuerte crecimiento de ingresos y estrategia...
10/02/2026 EXEL_US — GuruFocus
Decoding Exelixis Inc (EXEL): A Strategic SWOT Insight
10/02/2026 EXEL_US — GuruFocus
Q4 2025 Exelixis Inc Earnings Call Transcript
10/02/2026 EXEL_US — Insider Monkey
Why Exelixis (EXEL) is One of the Best Healthcare Stocks Under $50 to Invest In
10/02/2026 EXEL_US — Yahoo Finance
Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates
10/02/2026 EXEL_US — Investing.com
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion
09/02/2026 EXEL_US — ChartMill
EXELIXIS INC (NASDAQ:EXEL) Combines Strong Growth Fundamentals with Bullish Technical Setup
05/02/2026 EXEL_US — Yahoo Finance
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
03/02/2026 EXEL_US — Yahoo Finance
Should Value Investors Buy Exelixis (EXEL) Stock?
03/02/2026 EXEL_US — Yahoo Finance
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
02/02/2026 EXEL_US — Business Wire
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
02/02/2026 EXEL_US — Investing.com
FDA accepts Exelixis’ NDA for zanzalintinib in colorectal cancer
28/01/2026 EXEL_US — Seeking Alpha
Exelixis Stock Likely To Go Higher On A Possible Key FDA Approval (NASDAQ:EXEL)
27/01/2026 EXEL_US — GuruFocus ES ← EN
HC Wainwright & Co. eleva el precio objetivo de Exelixis (EXEL) a 52 dólares | Noticias de acciones de EXEL
26/01/2026 EXEL_US — ChartMill
Exelixis Inc (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity

Página 4 de 4

keyboard_arrow_up